Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
14/02/201813:19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
13/02/201816:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
13/02/201816:49Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
08/02/201815:01Business WireAcceleron Announces Appointment of Chief Commercial OfficerNASDAQ:XLRNAcceleron Pharma Inc
08/02/201809:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XLRNAcceleron Pharma Inc
31/01/201806:00Business WireAcceleron to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
08/01/201810:05Business WireAcceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral DystrophyNASDAQ:XLRNAcceleron Pharma Inc
08/01/201808:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
03/01/201806:00Business WireAcceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. ShermanNASDAQ:XLRNAcceleron Pharma Inc
02/01/201806:00Business WireAcceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
10/12/201708:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annu...NASDAQ:XLRNAcceleron Pharma Inc
05/12/201706:00Business WireAcceleron to Host Conference Call & Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meetin...NASDAQ:XLRNAcceleron Pharma Inc
28/11/201712:15Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
15/11/201715:01Business WireAcceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuireNASDAQ:XLRNAcceleron Pharma Inc
14/11/201715:01Business WireAcceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific ...NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:00Business WireAcceleron Pharma Reports Third Quarter 2017 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/11/201708:19Business WireAcceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and ExpositionNASDAQ:XLRNAcceleron Pharma Inc
26/10/201706:00Business WireAcceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017NASDAQ:XLRNAcceleron Pharma Inc
05/10/201706:00Business WireAcceleron Announces Closing of Underwriters’ Option to Purchase Additional SharesNASDAQ:XLRNAcceleron Pharma Inc
25/09/201715:26Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XLRNAcceleron Pharma Inc
21/09/201715:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:XLRNAcceleron Pharma Inc
20/09/201719:31Business WireAcceleron Announces Pricing of Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
19/09/201716:09Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:XLRNAcceleron Pharma Inc
19/09/201715:12Business WireAcceleron Announces Proposed Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
19/09/201715:09Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:XLRNAcceleron Pharma Inc
19/09/201710:30Business WireAcceleron Showcases Vision and Strategy at 2017 R&D DayNASDAQ:XLRNAcceleron Pharma Inc
19/09/201706:00Business WireAcceleron to Develop Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
12/09/201706:00Business WireAcceleron to Host Research and Development Day on September 19, 2017NASDAQ:XLRNAcceleron Pharma Inc
05/09/201706:00Business WireAcceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet OncologyNASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN